Australia's most trusted
source of pharma news
Thursday, 02 May 2024
Posted 16 April 2024 AM
Europe's medicines regulator, the EMA, has found no causal association between GLP-1 receptor agonists and the risk of suicidal thoughts and actions after a review which lasted close to nine months.
The investigation, triggered by the Icelandic medicines agency, originally looked at three Novo Nordisk's Saxenda and semaglutide products Ozempic, and Wegovy but was quickly extended to include Eli Lilly's Trulicity, AstraZeneca's Byetta.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.